1) we need NEW validated leads
2) we need clinical progress of VP-001
Stepping back as a third party observer - a fair read by the market on us = underwhelmed; slow, no surprise progress updates, milestones communicated via presentations still pending/delayed
as a shareholder - maybe I suffer from confirmation bias, but I believe 1st quarter 2022 is where we’ll hit some concrete milestones and deliver:
- 2 NEW validated leads which we will be confirmed to be taken to clinical via an aggressive parallel timeframe
- VP-001 announced milestones hit
- PYC extends platform to be a CNS pre-clinical player
Ann: Change in substantial holding, page-22
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
-0.065(5.08%) |
Mkt cap ! $566.9M | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.28 | $1.20 | $719.6K | 590.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 29750 | 1 |
View Market Depth
| Last trade - 16.10pm 13/01/2025 (20 minute delay) ? |
| PYC (ASX) Chart |
